Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study.

Systemic treatment modalities for eradication of multiple therapy resistant genital warts are so far not available. In this study laser treated patients with multiple genital warts received postoperatively either interferon alpha-2b subcutaneously (s.c.) 5 x 10(6) IU or matching placebo three times weekly for four weeks. At the conclusion of the study, 6-8 weeks after discontinuation of therapy, a significantly higher cure rate was found in the group of interferon-treated patients (14 of 27 (52%) patients cured) than among placebo treated patients (5 of 22 (23%) patients cured) (p less than 0.05). The side effects of fever, chills, myalgia, headache and leukopenia occurred more commonly in the interferon treated group than in the placebo group. However, only three of 32 patients discontinued interferon therapy because of side effects. We conclude that the addition of s.c. administered interferon alpha-2b to laser treated patients with chronic therapy resistant genital warts is fairly well tolerated and that it significantly enhances the chance of eliminating the disease.

[1]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[2]  C. Petersen,et al.  The patient with refractory genital warts in the STD-clinic. Treatment failure with CO2-laser. , 1990, Danish medical bulletin.

[3]  W. Derschum,et al.  Adjuvant-systemische Interferon-α2B-Behandlung bei therapieresistenten anogenitalen Condylomata acuminata , 1990 .

[4]  G. Scambia,et al.  Randomized Clinical Trial Comparing Systemic Interferon With Diathermocoagulation in Primary Multiple and Widespread Anogenital Condyloma , 1989, Obstetrics and gynecology.

[5]  R. Vollmer,et al.  Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. , 1989, Journal of the American Academy of Dermatology.

[6]  G. Krueger,et al.  Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. , 1988, Annals of internal medicine.

[7]  P. Larsen,et al.  Recombinant interferon alpha-2A (Roferon-A) in a case of Buschke-Löwenstein giant condyloma. , 1988, Dermatologica.

[8]  J. Mills,et al.  Interferon therapy for condylomata acuminata. , 1986, The New England journal of medicine.

[9]  K. Hatch,et al.  Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. , 1986, Archives of dermatology.

[10]  E. Schöpf,et al.  Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen. , 1986, Chemotherapy.